BioArctic AB (publ)

BioArctic AB (publ) is a Swedish biopharmaceutical firm heavily engaged in research, dedicated to creating biological therapies for individuals afflicted by neurodegenerative conditions. A primary candidate in their pipeline is BAN2401, an immunotherapy currently undergoing Phase III clinical evaluation for Alzheimer's disease, which targets harmful amyloid-beta oligomers and protofibrils. Furthermore, BAN2401 is being explored in preclinical studies for its potential in treating dementia associated with Down's syndrome and traumatic brain injury. A related compound, BAN2401 Back-up, is a disease-modifying antibody therapy in late preclinical development for early-stage Alzheimer's. The company's portfolio also includes ABBV-0805, a monoclonal antibody designed to address Parkinson's disease, and SC0806, a biodegradable device in Phase I/II clinical trials for spinal cord injuries. Beyond specific drug candidates, BioArctic is advancing biomarker technologies for diagnosing and monitoring Alzheimer's and Parkinson's diseases. They are also innovating with blood-brain-barrier technology to enhance the delivery of therapeutic antibodies and other agents into the brain. Their broader development efforts encompass ND3014 antibodies for various neurodegenerative disorders, alongside several other compounds for Alzheimer's (AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, AD2603) and Parkinson's disease (PD1601, PD1602). BioArctic maintains research collaborations with pharmaceutical giants Eisai and AbbVie. Established in 1992, the company was initially known as BioArctic Neuroscience AB before adopting its current name in 2016. It operates from its base in Stockholm, Sweden.